A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 683 participants.

Also called NCT05259033

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 683 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05259033
Other papers using this trial's data
  • Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial Diabetologia, 2025-04 DOI, PubMed 39820580, PMC11950020 PubMed links an erratum for this paper. Erratum: PMID 40323333 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Brazil, Canada, China, France, Greece, Hungary, Israel, Japan, Russia, Slovakia, Sweden, Switzerland, Taiwan, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05259033. Randomized; no masking; primary purpose treatment. Start 2022-04-11 (actual); primary completion 2023-12-13 (actual). Results posted on 2025-01-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
Acronym
COMBINE 2
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
IcoSema
Intervention (Drug)
Semaglutide 1 mg
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct05259033
Content hash
4792686b9341735842ab23e333b86ad4edfbb40e8b8f861c06cff604397bbc51